US FDA Investigators Focusing Inspections On Aseptic Processing Operations
Executive Summary
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.
You may also be interested in...
Cadila Shifts US Injectables Production From Plant After Tough FDA Inspection
Expert investigators found many problems at Ahmedabad plant, warning letter and Form 483 report show.
FDA warns Celltrion over its Incheon plant
Celltrion has received a warning letter from the US Food and Drug Administration (FDA) following an inspection of its manufacturing facility in Incheon, South Korea, carried out in May and June 2017. “The letter raises issues related to certain manufacturing processes at the facility,” Celltrion said. “We are making progress addressing these concerns, and we are committed to working with the agency to fully resolve all outstanding issues with the highest priority.”
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”